Frank McCormick discusses how each protein is a problem in the use of pharmaceutics to combat cancer and suggests that developing a platform that can be used for anything is the process that will alter the future of cancer treatment. (September 16, 2008)

Anthony Oro, MD, PhD, discusses how Hedgehog signally is a model for a variety of morphogenetic signals, that taking stem cells to effect wound healing may have an important role in pathogenesis. (September 16, 2008)

Dr. Saul Rosenberg discusses the history of diagnosis and treatment of Hodgkin's Disease and the remarkable improvement in curability since the 1960's. (September 15, 2008)

Stanford's Branimir Sikic discusses the importance of, and offers guidance to achieve the development of personalized medicines that are risk adapted genomic guided therapies which make a major impact on the disease. (September 15, 2008)

Dr. Michael Cleary discusses this work on the role of chromosomal aberrations in causing cancer and its implications for cancer treatment. (September 18, 2008)

Dr. John K. Chan, gyncecologic cancer specialist at the University of California - San Francisco Medical Center, discusses recent advances in the study of gynecologic cancers, focusing on novel therapeutics in ovarian cancer. (September 18, 2009)

Dr. Linda M. Boxer discusses her research on acute leukemia. (September 18, 2008)

Dr. James Brooks discusses his work on screening for and treatment of prostate cancer. (September 18, 2008)

Professor Christopher Contag discusses immune cell trafficking patterns as they relate to recognition of minimal residual disease. (September 16, 2008)

Dr. James Ford, Associate Professor of Medicine and Genetics at the Stanford University School of Medicine, discusses possibilities for using genetic testing to predict and manage the risks of certain cancers. (September 17, 2008)

Dr. Ellie Guardino discusses translational approaches to the development of targeted therapies and vaccines for the treatment and prevention of breast cancer. (September 18, 2008)

David Magnus, PhD, of the Stanford Center for Biomedical Ethics, discusses the abuse of ethics in scientific research. (September 17, 2008)

Stanford Professor of Medicine, Marcial L. Stefanick, PhD, discusses the history of research in prognosis and prevention of breast cancer and states the importance of healthy lifestyle choices. (September 17, 2008)

Professor of Radiation Oncology, Quynh-Thu Le, MD, discusses how translational research has improved understanding of HNC pathogenesis and prognosis, prognostication and surveillance for relapse. (September 18, 2008)

Alejandro Sweet-Cordero, MD, discusses the distinct biology of osteosarcoma and Ewing's sarcoma and posits that future treatment of these rare diseases will require better biology based therapies. (September 18, 2008)

Stanford Professor of Pathology and Developmental Biology, Irving Weissman, MD, PhD, explains the results of his research in hematopoietic and leukemic stem cells. (September 15, 2008)

Ronald Levy discusses the parallels between wound repair and regenerative medicine in cancer, and explores strategies to aid regenerative healing, prevent over-scarring, and heal critical sized defects through tissue engineering. (September 16, 2008)

Samuel Strober discusses several methods and keys to achieving tolerance in transplant patients as a process that takes time before immunosuppressant drugs can be withdrawn. (September 16, 2008)

Dr. Edgar Engelman discusses dendritic cell based immunotherapy, focusing on experimental cancer treatments. (September 16, 2008)

Dr. Dean Felsher discusses the role of oncogenes in the pathogenesis of cancer, the concept of oncogene addiction, and the therapeutic potential of treatments that inactivate particular oncogenes. (September 15, 2008)

Dr. James Hallenbeck discusses the history and future of palliative care research and how it overlaps with traditional oncology. (September 21, 2007)

Dr. Steve Leibel discusses what research is and how it is conducted at the Stanford Cancer Center. (September 21, 2007)

Dr. Roland Nusse discusses how Wnt protein signaling pathways relate to colon cancer and their importance. (September 21, 2007)

Dr. Linda Boxer discusses genetic mutations and how they can potentially activate oncogenes. (September 21, 2007)